Amrita Researcher Secures Top Honors at Ayurveda World Summit for Landmark Drug-Interaction Study

A PhD candidate from Amrita Vishwa Vidyapeetham has been awarded first prize at the 2nd Ayurveda World Summit for her groundbreaking research on the concurrent use of Ayurvedic formulations and conventional biomedicine. The study addresses critical safety and efficacy questions regarding integrative treatments for Rheumatoid Arthritis, marking a significant step forward in the scientific validation of traditional medicine.

The global medical community has long grappled with the “black box” of integrative medicine—the often-unseen chemical and physiological interactions that occur when a patient mixes ancient herbal traditions with modern pharmaceuticals. However, a new breakthrough from the Amrita Centre for Advanced Research in Ayurveda is shedding light on these complexities, potentially paving the way for a more unified approach to chronic disease management.

At the recently concluded 2nd Ayurveda World Summit in Bangalore, India, Dr. Sujithra M, a PhD candidate and Senior Research Officer at Amrita Vishwa Vidyapeetham’s School of Ayurveda, emerged as a leading voice in the field. Dr. Sujithra was awarded first prize in the highly competitive Paper Presentation (Oral) category, a distinction that underscores the growing academic rigor being applied to traditional Indian medicine.

Her research, titled “Drug-Herb Interaction Study of Ayurveda Formulation Amrittottaram Kashayam and Biomedicine Methotrexate Administered Concurrently in Patients with Rheumatoid Arthritis (RA),” tackles one of the most pressing dilemmas in contemporary rheumatology. Rheumatoid Arthritis (RA), a chronic inflammatory disorder that can cause joint destruction and functional disability, is frequently managed in the West with Methotrexate, a potent disease-modifying antirheumatic drug (DMARD). Despite its efficacy, Methotrexate often carries a heavy burden of side effects, leading many patients in Asia and Europe to supplement their treatment with Ayurvedic interventions.

The core of Dr. Sujithra’s inquiry was whether the Ayurvedic formulation Amrittottaram Kashayam—a decoction traditionally used for its anti-inflammatory and digestive properties—could be safely administered alongside Methotrexate without diminishing the drug’s efficacy or increasing its toxicity.

The findings presented at the summit suggest a high level of biomedical compatibility between the two systems. This is no small feat in a regulatory environment where medical professionals are often wary of “herb-drug interactions” (HDI). By utilizing rigorous clinical metrics and pharmacological analysis, the study provided a data-driven foundation for what practitioners of integrative medicine have long observed in clinical settings: that traditional and modern therapies can, when managed correctly, work in synergy.

The research was conducted under the sophisticated academic framework of Amrita Vishwa Vidyapeetham, an institution that has increasingly positioned itself at the intersection of spiritual tradition and cutting-edge science. The project was led by Dr. Zeena S Pillai, a Professor in the Department of Chemistry at the School of Physical Sciences, who served as the Principal Investigator. The interdisciplinary nature of the team—including co-guidance from Dr. Rajeshwari P N, a Professor in the Department of Shalya Tantra at Alva’s Ayurveda Medical College—highlights the multi-faceted approach required to validate Ayurvedic pharmacology in the 21st century.

For the pharmaceutical industry and the broader healthcare sector, the implications of Dr. Sujithra’s work are profound. If traditional formulations like Amrittottaram Kashayam can be proven to mitigate the side effects of drugs like Methotrexate—or even enhance their anti-inflammatory profile—the potential for hybrid treatment protocols becomes a reality. This could lead to a reduction in the dosage of synthetic drugs required to achieve remission in RA patients, thereby lowering the risk of long-term liver and kidney complications.

The 2nd Ayurveda World Summit serves as a critical forum for such discussions, bringing together researchers, policymakers, and practitioners to debate the future of the Ayush (Ayurveda, Yoga, Unani, Siddha, and Homeopathy) sector. In recent years, the Indian government has made a concerted effort to export Ayurveda as a scientific discipline rather than just a wellness lifestyle. Successes like Dr. Sujithra’s are essential to this soft-power and economic strategy, providing the “hard science” necessary to satisfy international regulatory bodies like the FDA or the European Medicines Agency.

The award also highlights the rising profile of Amrita’s School of Ayurveda. By encouraging PhD candidates to engage in high-level oral presentations and peer-reviewed scrutiny, the university is fostering a new generation of “bridge builders”—scientists who are equally fluent in the language of Sanskrit texts and molecular biology.

As the global burden of autoimmune diseases continues to rise, the demand for holistic, patient-centric care is escalating. Dr. Sujithra’s victory in Bangalore is more than a personal or institutional achievement; it is a signal to the global medical establishment that the wall between Ayurveda and Allopathy is beginning to crumble, replaced by a bridge built on the rigorous foundation of evidence-based research.

The next steps for the research team involve expanding the trial size and investigating the long-term metabolic pathways of these combined treatments. As the data matures, the medical community may soon see the day when a prescription for a synthetic DMARD comes standard with a companion Ayurvedic decoction, optimized for safety and maximized for healing.